Vor Biopharma (NYSE:VOR) Trading Down 2.7% – What’s Next?

Vor Biopharma Inc. (NYSE:VOR) fell 2.7% on Friday . The company traded as low as $0.95 and last traded at $1.08. 356,891 shares were traded during trading, a decline of 42% from the average session volume of 618,261 shares. The stock had previously closed at $1.11.

Analyst Ratings Changes

A number of research firms have weighed in on VOR. Wedbush restated an “outperform” rating and set a $11.00 price target on shares of Vor Biopharma in a research report on Monday, December 9th. JMP Securities restated a “market outperform” rating and set a $12.00 price target on shares of Vor Biopharma in a research report on Tuesday, December 10th. HC Wainwright restated a “buy” rating and set a $17.50 price target on shares of Vor Biopharma in a research report on Tuesday, December 10th. Finally, Robert W. Baird lowered their price target on Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating on the stock in a research report on Friday, November 8th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $11.36.

Vor Biopharma Stock Down 2.7 %

The stock has a market cap of $74.17 million, a PE ratio of -0.65 and a beta of -0.45. The company has a fifty day moving average price of $1.33 and a 200 day moving average price of $1.01.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. GABELLI & Co INVESTMENT ADVISERS INC. purchased a new position in Vor Biopharma during the 4th quarter valued at about $33,000. Virtu Financial LLC purchased a new position in Vor Biopharma during the 4th quarter valued at about $60,000. XTX Topco Ltd purchased a new position in Vor Biopharma during the 4th quarter valued at about $80,000. Rosalind Advisors Inc. purchased a new position in Vor Biopharma during the 3rd quarter valued at about $54,000. Finally, Trustees of Columbia University in the City of New York purchased a new position in Vor Biopharma during the 4th quarter valued at about $102,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.